Do autochthonous tumors interfere with effector T cell responses?

Seminars in Cancer Biology

Volumn 17, Issue 4, 2007, Pages 267-274

  Blankenstein, Thomas ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Autochthonous tumors; Cancer immunosurveillance; Effector T cells; Immunity; Tolerance

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EFFECTOR CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR VOLUME;

ANIMALS; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 34547689270     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2007.06.007     Document Type: Review

References (70)

1. Kast W.M., Offringa R., Peters P.J., Voordouw A.C., Meloen R.H., van der Eb A.J., et al. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59 (1989) 603-614
2. Spiotto M.T., Rowley D.A., and Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 10 (2004) 294-298
3. Greenberg P.D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49 (1991) 281-355
4. Deichman G.I. Immunological aspects of carcinogenesis by deoxyribonucleid acid tumor viruses. Adv Cancer Res 12 (1969) 101-136
5. Xe X., McCarrick J., Jewett L., and Knowles B.B. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc Natl Acad Sci USA 91 (1994) 3916-3920
6. Garbi N., Arnold B., Gordon S., Hammerling G.J., and Ganss R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol 172 (2004) 5861-5869
7. Willimsky G., and Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437 (2005) 141-146
8. Otahal P., Schell T.D., Hutchinson S.C., Knowles B.B., and Tevethia S.S. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. J Immunol 177 (2006) 3089-3099
9. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333 (1995) 1038-1044
10. Heslop H.E., Ng C.Y., Li C., Smith C.A., Loftin S.K., Krance R.A., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2 (1996) 551-555
11. Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 (1990) 2462-2465
12. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3 (2002) 999-1005
13. Drake C.G., Jaffee E., and Pardoll D.M. Mechanisms of immune evasion by tumors. Adv Immunol 90 (2006) 51-81
14. Schreiber H. Tumor immunology. In: Paul W.E. (Ed). Fundamental immunology. 3rd ed. (1993), Raven Press Ltd., New York 1143-1178
15. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991-998
16. Smyth M.J., Dunn G.P., and Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90 (2006) 1-50
17. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol 21 (2003) 807-839
18. Lloyd L.J. Cancer vaccine collaborative 2002: opening address. Cancer Immun 3 (2003) 1
19. Melief C.J.M. Cat and mouse games. Nature 437 (2005) 41-42
20. Yamaguchi T., and Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Sem Cancer Biol 16 (2006) 115-123
21. + T cell cytotoxicity and cancer. Sem Cancer Biol 16 (2006) 124-136
22. Zitvogel L., Tesniere A., and Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6 (2006) 715-727
23. Burnet F.M. Immunological factors in the process of carcinogenesis. Br Med Bull 20 (1964) 154-158
24. Burnet F.M. The concept of immunological surveillance. Progr Exp Tum Res 13 (1970) 1-27
25. Burnet F.M. Immunological surveillance in neoplasia. Transplant Rev 7 (1971) 3-25
26. Boon T., Coulie P.G., van den Eynde B.J., and van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 24 (2006) 175-208
27. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909-915
28. Klein G., and Klein E. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci USA 74 (1977) 2121-2125
29. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
30. + regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol 162 (2003) 691-702
31. DePinho R.A. The age of cancer. Nature 408 (2000) 248-254
32. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
33. Duesberg P.H. Are cancers dependent on oncogenes or on aneuploidy?. Cancer Genet Cytogenet 143 (2003) 89-91
34. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 (1998) 643-649
35. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95 (1998) 7556-7561
36. Qin Z., Kim H.J., Hemme J., and Blankenstein T. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon γ receptor-dependent foreign body reaction. J Exp Med 11 (2002) 1479-1490
37. Qin Z., and Blankenstein T. A cancer immunosurveillance controversy. Nat Immunol 5 (2004) 3-4
38. Stutman O. Immunodepression and malignancy. Adv Cancer Res 22 (1975) 261-422
39. Engel A.M., Svane I.M., Rygaard J., and Werdelin O. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol 45 (1997) 463-470
40. Blankenstein T., and Qin Z. Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance. Adv Cancer Res 90 (2003) 179-207
41. Street S.E., Trapani J.A., MacGregor D., and Smyth M.J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 196 (2002) 129-134
42. Enzler T., Gillessen S., Manis J.P., Ferguson D., Fleming J., Alt F.W., et al. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med 197 (2003) 1213-1219
43. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
44. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
45. Karin M., and Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5 (2005) 749-759
46. Erdman S.E., Rao V.P., Poutahidis T., Ihrig M.M., Ge Z., Feng Y., et al. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 63 (2003) 6042-6050
47. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 (2003) 203-213
48. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Miecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006) 1960-1964
49. Blohm U., Potthoff D., van der Kogel A.J., and Pircher H. Solid tumors "melt" from the inside after successful CD8 T cell attack. Eur J Immunol 36 (2006) 468-477
50. Klein G., Sjogren H.O., Klein E., and Hellstrom K.E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20 (1960) 1561-1572
51. van den Broek M.E., Kagi D., Ossendorp F., Toes R., Vamvakas S., Lutz W., et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 184 (1996) 1781-1790
52. + T-lymphocyte responses to multiple epitopes from Simian Virus 40 (SV40) Large T Antigen in C57BL/6 mice immunized with SV40, SV40 T-Antigen-transformed cells, or Vaccinia virus recombinants expressing full-length T Antigen or epitope minigenes. J Virol 74 (2000) 6922-6934
53. Schell T.D., Knowles B.B., and Tevethia S.S. Sequential loss of cytotoxic T lymphocyte responses to Simian Virus 40 Large T Antigen epitopes in T Antigen transgenic mice developing osteosarcomas. Cancer Res 60 (2000) 3002-3012
54. Adams T.E., Alpert S., and Hanahan D. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature 325 (1987) 223-228
55. Aichele P., Brduscha-Riem K., Oehen S., Odermatt B., Zinkernagel R.M., Hengartner H., et al. Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity 6 (1997) 519-529
56. Nguyen L.T., Elford A.R., Murakami K., Garza K.M., Schoenberger S.P., Odermatt B., et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med 195 (2002) 423-435
57. + T lymphocytes into effector CTL. J Immunol 172 (2004) 6558-6567
58. Old L.J., Boyse E.A., Clarke D.A., and Carswell E.A. Antigenic properties of chemically-induced tumors. Ann NY Acad Sci 101 (1962) 80-106
59. Gorelik E. Concomitant tumor immunity and the resistance to a second tumor challenge. Adv Cancer Res 39 (1983) 71-120
60. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5 (1999) 677-685
61. Lurguin C., Lethe B., De Plaen E., Corbiere V., Theate I., van Baren N., et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201 (2005) 249-257
62. Germeau C., Ma W., Schiavetti F., Lurguin C., Henry E., Vigneron N., et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201 (2005) 241-248
63. Blankenstein T., and Qin Z. The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol 15 (2003) 148-154
64. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 17 (2005) 180-186
65. Torre-Amione G., Beauchamp R.D., Koeppen H., Park B.H., Schreiber H., Moses H.L., et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87 (1990) 1486-1490
66. Gorelik L., and Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7 (2001) 1118-1122
67. Fu T.M., Mylin L.M., Schell T.D., Bacik I., Russ G., Yewdell J.W., et al. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive Simian Virus 40 Large T antigen cytotoxic T-lymphocyte epitope. J Virol 72 (1998) 1469-1481
68. Riethmuller G., Schneider-Gadicke E., and Johnson J.P. Monoclonal antibodies in cancer therapy. Curr Opin Immunol 5 (1993) 732-739
69. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
70. Schreiber K., Rowley D.A., Riethmuller G., and Schreiber H. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am 20 (2006) 567-584